Epivon

Monotherapy for partial onset seizures w/ or w/o secondary generalisation in patients ≥16 yr w/ newly diagnosed epilepsy. Adjunctive therapy for partial onset seizures w/ or w/o secondary generalisation in adults & childn ≥4 yr w/ epilepsy; myoclonic seizures in adults & adolescents ≥12 yr w/ juvenile myoclonic epilepsy; primary generalised tonic-clonic seizures in adults & adolescents ≥12 yr w/ idiopathic generalised epilepsy.

Monotherapy Adult & adolescent ≥16 yr Recommended starting dose: 250 mg bd, increase to an initial therapeutic dose of 500 mg bd after 2 wk. Can be further increased by 250 mg bd every 2 wk depending upon clinical response. Max dose: 1,500 mg bd. Adult weighing >50 kg w/ renal impairment: CrCl >80 mL/min/1.73 m² 500-1,500 mg bd, 50-79 mL/min/1.73 m² 500-1,000 mg bd, 30-49 mL/min/1.73 m² 250-750 mg bd, <30 mL/min/1.73 m² 250-500 mg bd, ESRD/patient undergoing dialysis 500-1,000 mg once daily. Loading dose: 750 mg on the 1st day of treatment. Supplemental dose: 250-500 mg following dialysis. Add-on therapy Adult & adolescent 12-17 yr weighing ≥50 kg Initially 500 mg bd. Can be increased up to 1,500 mg bd depending upon clinical response & tolerability. Dose changes can be made in 500 mg bd increases or decreases every 2-4 wk. Adolescent 12-17 yr & childn 4-11 yr weighing <50 kg Initially 10 mg/kg bd. Can be increased up to 30 mg/kg bd depending upon clinical response & tolerability. Dose changes should not exceed increases or decreases of 10 mg/kg bd every 2 wk; use lowest effective dose.

May be taken with or without food.

Hypersensitivity.

Anticonvulsants

N03AX14 - levetiracetam ; Belongs to the class of other antiepileptics.

POM